DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Companies / S••••• T••••••••• I••
S••••• T••••••••• I••
Series BSouth San Francisco, CAPharmaceuticals
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- Decline to Disclosesec.gov
- Rounds on record
- 2
- Disclosed raised
- $27.0Msum of rounds with a disclosed amount only
- Named investors
- 2
Financing history
2 rounds
- Apr 14, 2026Series B · $27.0M (disclosed)G••• I••••••••• (lead)U•••••• S•••••• G•••• (participant)Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “S••••• T••••••••• Announces $27 Million Series B Financing and Strategic Partnership with Advanced Bionics”
- Sep 30, 2025Form D equity offering · $27.1M (form d sold) · 34 investorsFact SEC EDGAR Form D data sets (quarterly) · “S••••• T••••••••• I•• filed Form D: $27,089,839 sold of $27,089,842, Pharmaceuticals”
Investors on record
2 edges
- G••• I••••••••• round, lead Fact prnewswire.com
- U•••••• S•••••• G•••• round, participant Fact prnewswire.com
People
2 officers, 7 directors
- E••••• d• J••• Executive Officer/Director sec.gov
- H••• P•••• Executive Officer/Director sec.gov
- D•••••••• X•••• Director Fact
- A••••• M••••••••• Director Fact
- W••••• T••••• Director Fact
- A•••••• A••••• Director Fact
- F••••••• G•••••• Director Fact
- J••••••••• P•••••• Director Fact
- G•• J••• S••••• G••••• Director Fact
Timeline
2
- Apr 16, 2026S••••• T••••••••• I•• filed Form D: $27,089,839 sold of $27,089,842, PharmaceuticalsForm D filed Fact SEC EDGAR Form D data sets (quarterly)
- Apr 14, 2026S••••• T••••••••• announced Series B of $27,000,000, led by G••• I•••••••••Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
15 observations
Every observation on this company
- Entity type: Corporation Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Form D industry group: Pharmaceuticals Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Amendment: false Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Revenue range (Form D): Decline to Disclose Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Incorporated: overFiveYears Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Jurisdiction: DELAWARE Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Amount sold (Form D): $27.1M Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Offering amount (Form D): $27.1M Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Exemptions: 06b Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- First sale: 2025-09-30 Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Investors (Form D): 34 Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Minimum investment (Form D): 0 Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Securities offered: equity Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Office address: 6000 SHORELINE COURT, SUITE 206, SOUTH SAN FRANCISCO, CA, 94080 Apr 16, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Round announced: Series B $27,000,000 Apr 14, 2026 Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)